TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
Events
AACR 2025 | Transcenta to Debut Preclinical Data of a Novel FGFR2b-targeting ADC
Transcenta to Present I/IIa Study Results of First-line Osemitamab (TST001) plus Nivolumab and CAPOX for Advanced G/GEJ Cancer at ASCO 2024
Transcenta to Present Osemitamab (TST001) and TST003 Study Results at AACR 2024
Transcenta 2023 R&D Day
Transcenta's CEO, Dr. Xueming Qian will be participating in Turning Science Into Business Submit: Cancer research opportunities and advances.
Transcenta to Present Three Study Results at ESMO 2023
2023 - 11 - 09 